- Details
- Cora Sternberg, MD, FACP, shares the final analysis of the PROSPER trial assessing enzalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC). In this double-blind, phase 3 trial, men with nonmetastatic, castration-resistant prostate cancer (defined on the basis of conventional imaging and a PSA doubling time of ≤10 months) who were continuing to receive androgen-deprivation ther...
|
- Details
- Darolutamide is a structurally unique androgen-receptor antagonist that is approved for the treatment of prostate cancer. ARAMIS is a randomized, double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic, castration-resistant prostate cancer, and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned in a 2:1 ratio to receive daroluta...
|
- Details
- Fred Saad provides his perspective on the newest ARAMIS trial results, presented at ASCO 2020. Results from the phase III androgen receptor inhibiting agent for metastatic-free survival (ARAMIS) trial that investigated darolutamide in men with non-metastatic castration-resistant prostate cancer (nmCRPC) showed a significant improvement in delaying the time to death in patients receiving darolutami...
|
- Details
- Evan Yu joins Alicia Morgans to discuss treatment advances in the non-metastatic castration-resistant prostate cancer space, focusing on the data and clinical implications of the ARAMIS trial. Biographies: Evan Yu, MD, Medical oncologist, treats prostate, bladder, and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies, as well as...
|
- Details
- In this conversation with Alicia Morgans, Neal Shore talks about the three new approved agents in the non-metastatic, castration-resistant prostate cancer (CRPC) setting; apalutamide, enzalutamide, and darolutamide and specifically highlight the urge for findings of prolonged survival, which have now been reported from both enzalutamide in the PROSPER trial and darolutamide in the ARAMIS trial. To...
|
- Details
- Karim Fizazi gives his insights into this evolving landscape of systemic therapies in both the non-metastatic castration-resistant and metastatic hormone-sensitive space. Dr. Fizazi discusses how therapies targeting the androgen receptor (AR) remains a critical focus in the treatment of prostate cancer. The data is showing that the introduction of these AR targeting drugs earlier in the course of...
|
- Details
- Tia Higano and Maha Hussain share highlights of their 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentations with Alicia Morgans. Drs. Higano and Hussain presented opposing presentations on the pros and cons of treatment in the nonmetastatic castration-resistant prostate cancer setting. Biographies: Maha Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in t...
|
- Details
- Nicholas James joins Alicia Morgans at the Advanced Prostate Cancer Consensus Conference (APCCC) to discuss systemic therapies for node-positive patients. Professor James discusses the three main questions to his presentation: What's the role of radiotherapy? What systemic therapies do you give with radiotherapy? Do you give ADT plus something else? Biographies: Professor Nicholas James BSc, MB, B...
|
- Details
- Nick James and Alicia Morgans talk about the newly presented STAMPEDE data just released and presented at the 2019 ESMO meeting including, long-term follow-up of the docetaxel patients as well as the much anticipated metastatic data. Biographies: Professor Nicholas James BSc, MB, BS, FRCP, FRCR, Ph.D., Institute of Cancer and Genomic Sciences NIHR Senior Investigator, Consultant in Clinical Oncolo...
|
- Details
- Noel Clarke presented on the optimization of the treatment of newly diagnosed metastatic prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Among the topics he covers in this presentation include the STAMPEDE biomedical imaging group (BIG) and STAMPEDE biomedical research group (BRG) which have incorporated 5,000 CT and bone scans with a target of more than 10,000,...
|
